Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Buspirone
Drug ID BADD_D00316
Description Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class,[A180991] buspirone is a serotonin 5-HT1A receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs.[L4478] Unlike many drugs used to treat anxiety, buspirone does not exhibit anticonvulsant, sedative, hypnotic, and muscle-relaxant properties. Due to these characteristics, buspirone been termed 'anxioselective'.[A180985] First synthesized in 1968 then patented in 1975,[L7375] it is commonly marketed under the brand name Buspar®. Buspirone was first approved in 1986 by the FDA [A181751] and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety. It has also been used as a second-line therapy for unipolar depression when the use of selective serotonin reuptake inhibitors (SSRIs) is deemed clinically inadequate or inappropriate.[L7375] The potential use of buspirone in combination with [melatonin] in depression and cognitive impairment via promoting neurogenesis has also been investigated.[A181751]
Indications and Usage Indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety.[L4478]
Marketing Status approved; investigational
ATC Code N05BE01
DrugBank ID DB00490
KEGG ID D07593
MeSH ID D002065
PubChem ID 2477
TTD Drug ID D0U2OO
NDC Product Code Not Available
UNII TK65WKS8HL
Synonyms Buspirone | N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide | Buspirone Hydrochloride | Hydrochloride, Buspirone | Gen-Buspirone | Gen Buspirone | Lin-Buspirone | Lin Buspirone | MJ-9022-1 | MJ 9022 1 | MJ90221 | Neurosine | Busp | Nu-Buspirone | Nu Buspirone | PMS-Buspirone | PMS Buspirone | Ratio-Buspirone | Ratio Buspirone | Anxut | Apo-Buspirone | Apo Buspirone | Buspar | Bespar | Novo-Buspirone | Novo Buspirone
Chemical Information
Molecular Formula C21H31N5O2
CAS Registry Number 36505-84-7
SMILES C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ejaculation delayed21.03.01.001--Not Available
Enuresis19.07.04.001; 20.02.02.003--Not Available
Eosinophilia01.02.04.001--
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.001--Not Available
Euphoric mood19.04.02.006--
Extrapyramidal disorder17.01.02.007--
Eye pain06.08.03.002--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.002--
Fear19.06.03.001--Not Available
Feeling abnormal08.01.09.0140.000143%Not Available
Flatulence07.01.04.002--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.002--
Galactorrhoea21.05.02.002; 05.03.04.002--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Glossodynia07.14.02.001--Not Available
Haemoglobin13.01.05.018--Not Available
Haemorrhagic disorder24.07.01.021; 01.01.03.004--Not Available
Hallucination19.10.04.003--
Hallucination, visual19.10.04.0070.000053%Not Available
Headache17.14.01.001--
Hiccups22.12.01.001; 07.01.06.009--
Hostility19.05.01.003--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages